July 27, 2017 06:55 AM EDTUpdated 09:44 AM
Financing

Si­en­na Bio bags $65M in the lat­est suc­cess­ful biotech IPO

John Carroll

Editor & Founder

Bustling along with a pipeline of ther­a­pies for var­i­ous skin con­di­tions, Si­en­na Bio­phar­ma­ceu­ti­cals has raised about $65 mil­lion from its IPO af­ter pric­ing 4 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Ei­sai ter­mi­nates Phase 3 tri­al of Dravet drug, cit­ing re­cruit­ment chal­lenges

Boston Phar­ma­ceu­ti­cals hits Phase 2 goals as it tries to keep up with MASH com­peti­tors

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times